India, March 21 -- American drugmaker Eli Lilly and Company launched its weight-loss injectable drug Mounjaro in India on Thursday, becoming the first multinational pharma firm to bring a treatment already widely used in Western markets to India, where obesity and associated type-2 diabetes poses a major health burden. Launched as a once-weekly injection, the drug is priced at Rs.4,375 for a 5mg vial and Rs.3,500 for a 2.5mg vial, the company said separately. Mounjaro has already gained popularity in the US, UK and European markets. Since the CDSCO authorisation, Indian patients had been importing the drug for personal use prior to the India launch, which helps bring the cost down. P8...